BSH22-PO108 Tranexamic Acid use to improve outcomes in Meningioma Surgery

Published Date: 31st March 2022

Publication Authors: Keshwara S

Introduction
Meningioma surgery is associated with intraoperative bleeding and large transfusion requirement. Tranexamic Acid (TXA) has been used in medical and surgical practice to reduce haemorrhage. This review aimed to evaluate the effect of TXA use on operative and postoperative outcomes.

Methods
A systematic review and meta-analysis was conducted in accordance with the PRISMA statement and registered in PROSPERO (CRD42021292157). Six databases were searched up to November 2021 for phase 2–4 clinical trials and multiple arm cohort studies. Random effects meta-analysis were performed to delineate operative (e.g intraoperative blood loss) and postoperative outcomes (e.g. postoperative complications).

Results
Four studies (181 patients) were included. TXA use significantly reduced intraoperative blood loss (mean difference 315.69 mls [95% CI -532.94 to −98.54]) and transfusion requirement (OR 0.52 [95% CI 0.27–0.98]). Factors not affected by TXA use were operation time (mean difference = −0.11 [CI 95% -0.27 to 0.05]), postoperative seizures (OR = 0.87 [CI 95% 0.31, 2.49]), hospital stay (OR = -1.24 [CI 95% -3.38 to 0.90]) and disability after surgery (OR = 0.53 [CI 95% 0.26, 1.04]).

Conclusions
Four studies (181 patients) were included. TXA use significantly reduced intraoperative blood loss (mean difference 315.69 mls [95% CI -532.94 to −98.54]) and transfusion requirement (OR 0.52 [95% CI 0.27–0.98]). Factors not affected by TXA use were operation time (mean difference = −0.11 [CI 95% -0.27 to 0.05]), postoperative seizures (OR = 0.87 [CI 95% 0.31, 2.49]), hospital stay (OR = -1.24 [CI 95% -3.38 to 0.90]) and disability after surgery (OR = 0.53 [CI 95% 0.26, 1.04]).

 

Clynch, A; Keshwara, S et al. (2022). BSH22-PO108 Tranexamic Acid use to improve outcomes in Meningioma Surgery. British Journal of Haematology. 197 (Suppl 1), 151

« Back